Locations:
SearchLifeArc and Cleveland Clinic sign 10-year Master Services Agreement to develop novel monoclonal antibody-based therapeutics, building on their successful collaboration since 2019. The agreement combines LifeArc's three decades of expertise in antibody humanization with Cleveland Clinic's renowned capabilities, aiming to address unmet medical needs in areas including cancer and complement-mediated diseases.
LifeArc and Cleveland Clinic have entered a 10-year Master Services Agreement (MSA) focused on developing innovative monoclonal antibody-based therapeutics. This MSA builds upon their existing collaborative relationship, which began in 2019 and has already yielded several successful humanization projects. The agreement leverages LifeArc's expertise in antibody humanization alongside Cleveland Clinic's research capabilities to target various conditions, including cancer and complement-mediated diseases.
The collaboration brings together two powerhouses in medical innovation: Cleveland Clinic, a globally recognized academic medical center, and LifeArc, a UK-based non-profit that brings over three decades of experience in antibody humanization and engineering. LifeArc's track record includes contributions to five licensed medicines currently on the market.
Both organizations express optimism about the potential impact of the collaboration. Dr. Jason Slingsby, Chief Business Officer at LifeArc, emphasizes the groundbreaking nature of this collaboration and its potential to develop new clinical candidate monoclonal antibodies, while Feng Lin, PhD, from Cleveland Clinic's Lerner Research Institute, highlights the complementary expertise both teams bring to the collaboration. This long-term commitment represents a significant step forward in addressing unmet medical needs through innovative therapeutic approaches.
Read LifeArc’s full press release here.
